| Document |
Document Title |
|
WO/2024/085671A1 |
The present application relates to a mutant ribonuclease activity regulating protein and a method for producing L-valine using same.
|
|
WO/2024/086298A2 |
Provided herein are HLA-class I and HLA-class II restricted and non-restricted epitopes recurrently identified in patients with cancer, that can be presented to T cell receptor (TCR) to induce polyfunctional T cell response, polyepitopes...
|
|
WO/2024/083224A1 |
The present invention discloses compounds of Formula (I) and their complexes with radionuclides that can recognize both Somatostatin type 2 receptor (SSTR2) and cholecystokinin 2 receptor (CCK2R) and can be used in the diagnosis and trea...
|
|
WO/2024/086842A2 |
The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising a first antigen-recognizing receptor (e.g., a chimeric antigen receptor ...
|
|
WO/2024/086557A1 |
Methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
|
|
WO/2024/086683A2 |
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of Lachnospiraceae flagellin peptides, which can be s...
|
|
WO/2024/085533A1 |
The present invention pertains to: a composition for improving the efficiency of introducing vectors into cells by using lunasin; and a method for introducing vectors into cells with high efficiency by using said composition.
|
|
WO/2024/086190A1 |
The disclosure relates to chimeric antigen receptor (CAR) specific to CD 19, vectors encoding the same, and recombinant T cells comprising the CD 19 CAR. The disclosure also includes methods of administering a genetically modified T cell...
|
|
WO/2024/083226A1 |
An activatable antibody fusion protein, said fusion protein comprising an antibody portion specifically binding to a target, an immunoglobulin Fc portion, a masking portion and a cytokine portion. The present invention further relates to...
|
|
WO/2024/083988A1 |
The present disclosure provides single domain antibodies (VHH or nanobodies) and conjugates thereof which are able to inhibit binding between PD-L1 and PD-1 with high efficiency. The disclosure additionally refers to viral vectors compri...
|
|
WO/2024/083912A1 |
The present invention relates to YGHJ polypeptides with novel glycosylation patterns. The glycosylated polypeptides are expressed in an avirulent genetically altered strain of the natural pathogenic bacteria, which gives rise to glycosyl...
|
|
WO/2024/085480A1 |
The present invention relates to: lactic acid bacteria extracellular membrane protein PrsA having a cell surface display anchor motif function; and a vector system for cell surface display of a target protein, the system comprising a seq...
|
|
WO/2024/084432A1 |
Provided are recombinant fusion proteins and compositions and uses thereof, the recombinant fusion protein including an interleukin-2 mutein and an antigen-binding fragment to serum albumin. The recombinant fusion protein has the advanta...
|
|
WO/2024/086191A2 |
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL...
|
|
WO/2024/082178A1 |
Provided is a chimeric antigen receptor, comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain targets CD19, and the second antigen-binding domain targets CD22. Also provi...
|
|
WO/2024/086747A1 |
The present disclosure provides a modified AAV capsid protein comprising a targeting peptide in variable region VIII (VR VIII). The modified AAV capsid protein can form an rAAV, which has a preferred tropism, specificity or biodistributi...
|
|
WO/2024/086680A2 |
The present invention relates to Atrial Natriuretic Peptide (ANP) polypeptides and methods of treatment with ANP polypeptides.
|
|
WO/2024/086169A2 |
Novel compositions of TCR Gamma Alternate Reading Frame Protein (TARP) peptides combined with cationic lipids such as the DOTAP and specifically R-DOTAP, induce high levels of TARP-specific polyfunctional cytolytic T-cells. Compositions ...
|
|
WO/2024/082795A1 |
The present invention relates to a protein and a vaccine against infections of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, which belong to the field of medicines. In order to solve the problem of lack of effective prevent...
|
|
WO/2024/086549A1 |
This invention relates chimeric alphavirus genomes, alphavirus particles and compositions comprising the same, and their use in methods of directed evolution, such as methods of modify a heterologous nucleic acid, evolving a heterologous...
|
|
WO/2024/084054A1 |
The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, each segment being operably linked t...
|
|
WO/2024/084497A1 |
The present disclosure relates to manufacturing transferrin binding proteins. Specifically, the present disclosure relates to a simple, scalable, commercially viable fermentation and purification process for obtaining recombinant transfe...
|
|
WO/2024/083973A1 |
The present invention relates to a host cell. The host cell finds utility as a biosensor by comprising at least one nucleic acid modification in the nucleic acid sequence of at least one gene. Also disclosed is the host cell for use as a...
|
|
WO/2024/086290A2 |
Provided herein are multiepitope peptides including at least one mucin 1 (MUC1) peptide, the multiepitope peptides have MHC affinity for at least one of HLA serotype and are recognized by a CD4+ T cell receptor and/or by a CD8+ T cell re...
|
|
WO/2024/082005A1 |
The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising the...
|
|
WO/2024/086628A2 |
Described herein are compositions and kits comprising recombinant adeno- associated viruses (rAAVs) with increased transduction enrichment in the brain and, in some cases, reduced transduction in the liver. The rAAV compositions describe...
|
|
WO/2024/086171A1 |
The present invention provides a bone graft such as an allograft and a method for releasing growth factors from tissues (e.g., bone marrow, bone matrix, periosteum, and/or endosteum) having native living cells. Also provided are a compos...
|
|
WO/2024/084082A1 |
The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of...
|
|
WO/2024/086781A2 |
According to some aspects, systems and methods for characterizing phosphoserine-containing polypeptides are described. In some embodiments, a phosphoserine residue of a polypeptide may be converted to a dehydroalanine residue. Some aspec...
|
|
WO/2024/086400A1 |
This disclosure relates to a modified oncolytic herpes simplex virus (oHSV) comprising an expression cassette encoding a histidine-rich glycoprotein (HRG), and uses thereof. One promising avenue for the treatment of cancer is oncolytic v...
|
|
WO/2024/086518A2 |
The present disclosure provides methods and compositions for tunable differentiation of hematopoietic stem and progenitor cells (HSPCs) in response to small molecules by using genetically modified HSPCs that express chimeric transmembran...
|
|
WO/2024/086738A2 |
Described herein are compositions and methods related to identification of incorporation of non-standard amino acids into proteins using inteins. Also described herein are methods related to development of modified IntN and IntC.
|
|
WO/2024/084041A2 |
The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in ...
|
|
WO/2024/083985A1 |
The present invention relates to novel peptides (cPEPs & altPEPs), to a method for the preparation thereof, and to the use thereof for modulating the accumulation of specific proteins.
|
|
WO/2024/084075A1 |
The present invention relates to the combination of a nucleic acid encoding a short isoform of rod- derived cone viability factor (RdCVF), a nucleic acid encoding a long isoform of rod-derived cone viability factor (RdCVFL) and a nucleic...
|
|
WO/2024/081994A1 |
The present disclosure relates to the field of protein-based inhibitors. More particularly, the present disclosure relates to protein inhibitors for the specific binding of PD-L1 and inhibition of PD-1/PD-L1 signalling. Additionally, thi...
|
|
WO/2024/084398A2 |
The present disclosure relates generally to polynucleotides, vectors, and cells for producing alpha 2 macroglobulin (A2M), methods of making A2M, and compositions comprising A2M. The present disclosure relates generally to polynucleotide...
|
|
WO/2024/083097A1 |
Disclosed in the present invention is an IL-2 mutant, having at least one of the following mutations on an amino acid sequence of IL-2: 1) an insertion of at least one amino acid residue having a smaller side chain between positions T10 ...
|
|
WO/2024/085723A1 |
The present application relates to a protein structure and a use thereof for a vaccine for prevention or treatment of coronavirus SARS-CoV-2 infectious disease, the protein structure comprising: a first recombinant protein having a SARS-...
|
|
WO/2024/085375A1 |
The present invention relates to the manufacture and application of flagellin immunopotentiating derivatives with TLR5 activity using an eukaryotic cell expression system. The flagellin derivative according to the present invention has a...
|
|
WO/2024/086827A2 |
According to various aspects of this disclosure, the present disclosure relates a fusion protein comprising i) an antigen-binding portion that binds CD8; and ii) a portion having an IL-2 activity ("IL-2 portion").
|
|
WO/2024/086826A2 |
Provided herein are compounds of Formulae (I) and (II), which comprise polypeptidyl groups. Also provided herein are methods of preparing compounds of Formulae (I) and (II). Further provided herein are methods of sequencing a polypeptide...
|
|
WO/2024/083888A2 |
The present invention provides a method for producing polyhydroxyalkanoate (PHA) from polyester waste, the method comprising the steps of: (a) providing a culture broth comprising polyester waste; and (b) cultivating a microbe in the cul...
|
|
WO/2024/086841A2 |
The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising a first antigen-recognizing receptor that targets CD70. These cells have...
|
|
WO/2024/086775A2 |
Truncated dominant negative forms of CEBPB and CEBPD, and cell-penetrating forms thereof are described. Methods for using the truncated dominant negative forms of CEBPB and CEBPD proteins, and cell-penetrating forms thereof, for decreasi...
|
|
WO/2024/085686A1 |
The present invention relates to: a recombinant protein comprising a foot-and-mouth disease virus (FMDV) virus-like particle (VLP) and the fragment crystallizable (Fc) region of a porcine-derived immunoglobulin linked to the surface of t...
|
|
WO/2023/240247A9 |
The present disclosure is directed, in part, to saxiphilin proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, and methods of detecting toxin in samples and for diagnosing a subject as c...
|
|
WO/2024/084852A1 |
The present invention relates to a nucleic acid molecule having a nucleotide sequence that encodes a chimeric antigen receptor (CAR). The present invention relates to a vector containing said nucleic acid molecule. The present invention ...
|
|
WO/2024/083986A1 |
The present invention relates to new peptides (cPEPs), a method for their preparation, and their use for modulating the accumulation of specific proteins.
|
|
WO/2024/082067A1 |
Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus ...
|
